AstraZeneca/Actavis Antibiotic Faces Limited Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA allowed flexibility in AstraZeneca/Actavis’ gram-negative antibiotic development program, but agency’s advisory committee briefing documents propose more restrictive label than companies are seeking.
You may also be interested in...
FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
Drugs From Sponsors ‘Located in Russia,’ Would Be Barred From US FDA Review By House Funding Bill
Language of the amendment cleared by appropriators in response to the Russian war against Ukraine in FDA’s fiscal year funding bill is vague, making impact of the funding ban on industry unclear. Democrats supported the amendment but said they wanted to continue to work on language to avoid “unintended consequences.” FDA would get a 10% bump in non-user fee funds under the bill.
US FDA Leaves Pfizer’s Efficacy Data Out Of Under 5 EUA Due To ‘Data Maturity,’ Lack of ‘Confidence’
Moderna’s ‘more mature’ vaccine efficacy data in children under 6 get agency highlight due to what Peter Marks called a ‘confidence’ difference in the numbers, the but CBER chief also said differences between Moderna’s and Pfizer’s vaccines are ‘subtle’ in this age group.